RecruitingNCT06236464

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas of the Anogenital Tract and of the Head-neck Region for the Development of Shared Therapeutic Strategies

Sponsor

National Cancer Institute, Naples

Enrollment

170 participants

Start Date

Sep 25, 2023

Study Type

OBSERVATIONAL

Conditions

Squamous Cell Carcinoma of the Head and Neck Squamous Cell Carcinoma of the Anus

Summary

This is a multicentric, retrospective, and prospective biomarker study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This research study is collecting tissue samples from patients with squamous cell carcinoma (a type of cancer) of the anus, cervix, vulva, or head and neck region, to study the biological mechanisms that cause these cancers to develop. **You may be eligible if...** - You are 18 or older - You are scheduled for surgery for squamous cell carcinoma of the anus, cervix, vulva, or head/neck area (including early or invasive stages) - You are willing and able to give written consent **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You are receiving treatment for another cancer at the same time - You have a weakened immune system due to a congenital condition, HIV, or organ transplant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMultiparameter analysis of each sample

Retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.